For Immediate Release
Anitra B. Johnson
FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies Wins 2013 CMO Leadership Awards for Industry Choice Awards in Productivity and Regulatory
MORRISVILLE, N.C. , April 4, 2014 – On March 12, 2014, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a global Biologics Contract Development and Manufacturing Organization, was recognized for Life Science Leader’s 3rd annual CMO Leadership Awards in the categories of Productivity and Regulatory as well as Industry Choice Award winners in Productivity and Regulatory.
“We are honored to be recognized for the 2013 CMO Leadership Awards in the categories of regulatory and productivity. Quality sets the foundation of everything we do to ensure patient safety and this is exemplified by our successful inspection history at our U.S.A. and U.K. sites. As a global leader in the contract development and manufacture of biopharmaceuticals, we look forward to building on this reputation.” — Stephen Spearman, Ph. D., MBA, President, FUJIFILM Diosynth Biotechnologies, U.S.A, Inc.
Life Science Leader magazine’s 3rd annual CMO Leadership Awards reception and ceremony were held at the W Hotel in New York. The CMO Leadership Awards are decided based on industry-leading market research conducted by Nice Insight. Over 40,000 pharmaceutical and biopharmaceutical executives are invited to participate in the annual survey and over 10,000 responded. Responses were compiled and analyzed to identify awareness and perception scores for CMOs serving the pharmaceutical and biopharmaceutical industry that are included in the survey. CMO Leadership Awards recognize CMOs with customer perception scores in the top 20% percentile in the areas of Quality, Innovation, Productivity, Regulatory, and Reliability. This year there was the addition of the Industry Choice Awards, which revealed the top-scoring company for each of five industry-driver categories. FUJIFILM Diosynth Biotechnologies received TWO Industry Choice Awards in Productivity and Regulatory.
These awards reflect the common filters used by Pharma companies to vet CMOs – with the added filter of peer feedback. This will help Pharma companies focus on potential CMO partners that can handle their projects and are considered the most reputable in the industry. For more information visit: www.cmoleadershipawards.com
About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies U.S.A., Inc. is an industry leading Biologics Contract Development and Manufacturing Organization. Fujifilm Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from cell line development, including its proprietary pAVEway™ system to process development, analytical development, clinical and commercial manufacturing. Fujifilm Diosynth Biotechnologies is also located in Billingham, UK as FUJIFILM Diosynth Biotechnologies UK Limited. Both sites have been FDA-approved for the production of commercial products. For more information, please visit: www.fujifilmdiosynth.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading–edge products to a broad spectrum of industries. In addition to fine digital cameras and photographic products, Fujifilm’s core fundamental technologies are applied in the fields of medical imaging and information, graphic arts equipment, data storage, electronic materials, pharmaceuticals and much more. The company was among the top 10 companies around the world granted U.S. patents in 2012, and in the fiscal year ended March 31, 2013, had global revenues of $26.7 billion. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.
* At an exchange rate of 83 yen to the dollar.
Company Interview with Dan DeVido (Director Commercial Development, FUJIFILM Diosynth Biotechnologies); and Todd Schnick and Todd Youngblood with Dreamland Interactive.
All product and company names herein may be trademarks of their registered owners.